Novo Nordisk joins the Call to Action for gender equality

Novo NordiskYesterday, the Danish Minister for Development Cooperation Ms Ulla Tørnæs handed over a torch to Executive Vice President Lise Kingo, Novo Nordisk, at a ceremony in Copenhagen. With the torch Ms Tørnæs makes a Call to Action to leaders from around the world to help accelerate progress on the Millennium Development Goal 3 (MDG3): To empower women and promote gender equality.

"The private sector plays a critical role if we are to improve women's situation. They have the availability to promote women’s opportunities within their field of work. I am therefore glad that Novo Nordisk now has joined our global Call to Action to accelerate progress on gender equality. The company has committed to drive actions that can improve the situation for women living with diabetes in the developing world. This is the kind of action we need from all actors," says Ulla Tørnæs, Danish minister for Development Cooperation.

As torch bearer Novo Nordisk is committed to creating awareness of how diabetes will impede development and women empowerment. This will be supported by actions to effectively overcome this barrier by improved prevention, diagnosis and treatment. Addressing the adverse relationship between the global diabetes epidemic and a healthy, sustainable development is Novo Nordisk's contribution to the achievement of MDG3.

"Women are uniquely affected by diabetes that all over the world results in life-threatening complications. Women have a higher diabetes-related morbidity and mortality due to biological, cultural and socioeconomic factors. If acquired during pregnancy, diabetes causes serious problems for both the mother and the child. Moreover, women are often at a disadvantage getting diagnosed and receiving proper treatment. We simply need to change diabetes for women," says Lise Kingo.

Lise Kingo is a member of the MDG3 Champion Network established by Ms Ulla Tørnæs among other things to bring global attention to MDG3. The network has participation by internationally prominent politicians, public and private sector leaders as well as civil society representatives.

On 24 September, Novo Nordisk co-hosts a Leadership Forum on Women, Diabetes and Development in New York, organised together with the Danish minister for Development Cooperation, The Global Alliance for Women's Health and the World Diabetes Foundation.

About Novo Nordisk
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,300 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit www.novonordisk.com.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

SMi Group announces the 9th Annual RNA Therapeutic…

21 - 22 February 2018, London, UK. As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]